8-K: Tonix Pharmaceuticals Secures Dual Manufacturing Partners for Potential Tonmya Launch

Tonix Pharmaceuticals has selected two contract manufacturing organizations, including Almac Pharma Services, to support the potential launch and commercialization of its fibromyalgia drug, Tonmya.

Summary

• Tonix Pharmaceuticals has chosen two contract manufacturing organizations (CMOs) to ensure a reliable supply chain for the potential launch of Tonmya.
• One of the selected CMOs is Almac Pharma Services, which has previously supported the development and clinical trials of Tonmya.
• Tonmya is a non-opioid medication being developed for the management of fibromyalgia, with positive results from two Phase 3 clinical trials.
• The company plans to submit a New Drug Application (NDA) to the FDA in the second half of 2024.
• Tonmya is a sublingual tablet containing 2.8 mg of cyclobenzaprine HCl, with a planned dosage of one tablet daily for two weeks, then potentially increasing to two tablets daily.
• The medication is designed for bedtime administration and has a predicted shelf life of over 48 months at room temperature.
• Commercial distribution is planned in 14, 60, and 90 count tablet bottles.

Sentiment

Score: 7

Explanation: The document is positive due to the progress in manufacturing and the planned NDA submission, but it also includes standard risk disclosures, which temper the overall sentiment.

Positives

• The selection of two CMOs provides dual sourcing, which is critical for successful commercial launch and supply chain management.
• Tonmya has shown positive results in two Phase 3 clinical trials, indicating its potential efficacy in managing fibromyalgia.
• The drug is a non-opioid, non-addictive medication, addressing a need for alternative pain management options.
• The sublingual tablet formulation offers rapid systemic exposure and a long predicted shelf life.
• The planned commercial distribution in multiple bottle sizes allows for flexible and chronic supply.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including the failure to obtain FDA approvals.
• There are risks related to the successful marketing of the product and the timing of clinical development.
• The company faces competition and requires additional financing.
• There are uncertainties related to patent protection and reimbursement.

Future Outlook

Tonix plans to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for Tonmya for the management of fibromyalgia.

Management Comments

• Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, stated that dual sourcing is a critical element for the successful commercial launch and supply chain management of a product.
• Mark English, VP Operations, Almac Pharma Services, expressed excitement to continue their partnership with Tonix to support the commercial launch and ongoing supply of Tonmya.

Industry Context

This announcement is significant as it indicates progress in Tonix's efforts to bring Tonmya to market, addressing the need for non-opioid pain management options for fibromyalgia. The selection of dual manufacturing partners is a standard practice in the pharmaceutical industry to mitigate supply chain risks.

Comparison to Industry Standards

• The selection of two CMOs is a common practice in the pharmaceutical industry to ensure supply chain redundancy, similar to how companies like Pfizer and Moderna have used multiple manufacturing partners for their vaccines.
• The planned NDA submission in the second half of 2024 is a typical timeline for a drug that has completed Phase 3 trials, comparable to other companies developing new treatments for chronic conditions.
• The focus on a non-opioid treatment for fibromyalgia aligns with the industry trend of seeking alternatives to opioids for pain management, similar to the efforts of companies like Biohaven and Eli Lilly in developing non-opioid migraine treatments.

Stakeholder Impact

• Shareholders may view this announcement positively as it indicates progress towards commercialization.
• Patients with fibromyalgia may benefit from a new non-opioid treatment option.
• The company's employees are involved in the development and commercialization of Tonmya.
• The selected CMOs, including Almac Pharma Services, will benefit from the manufacturing contract.

Next Steps

• Tonix plans to submit a New Drug Application (NDA) to the FDA in the second half of 2024.
• The company will work with the selected CMOs to prepare for the potential commercial launch of Tonmya.

Key Dates

Keywords

Tonix Pharmaceuticals, Tonmya, Fibromyalgia, Contract Manufacturing Organization, Almac Pharma Services, NDA, Phase 3 Trial, Non-opioid, Sublingual Tablet, Commercialization